Clinical Significance of Background Parenchymal Enhancement in Breast Cancer Risk Stratification

By sjmartinez • September 20, 2023

Murakami W, Mortazavi S, Yu T, Kathuria-Prakash N, Yan R, Fischer C, McCann KE, Lee-Felker S, Sung. Clinical Significance of Background Parenchymal Enhancement in Breast Cancer Risk Stratification. J Magn Reson Imaging. 2023 Sep 19. doi: 10.1002/jmri.29015. Epub ahead of print. PMID: 37724902.

Tags: background parenchymal enhancement (BPE), BRCA, breast MRI, Fellow, Hematology/Oncology, high-risk screening, lifetime risk, Publications

Elevated serum levels of GPX4, NDUFS4, PRDX5, and TXNRD2 as predictive biomarkers for castration resistance in prostate cancer patients: an exploratory study

Wang R, Wang S, Mi Y, Huang T, Wang J, Ni J, Wang J, Yin J, Li M, Ran X, Fan S, Sun Q, Tan[...]

Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies

Li YR, Fang Y, Niu S, Zhu Y, Chen Y, Lyu Z, Zhu E, Tian Y, Huang J, Rezek V, Kitchen S, Hsiai T, Zhou[...]

Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas

Wilky BA, Schwartz GK, Gordon MS, El-Khoueiry AB, Bullock AJ, Henick B, Agulnik M, Singh A, Mahadevan D, Stebbing J, Delepine C, Chand D, Avagyan[...]